Triple-negative breast cancers (negative for expression of the oestrogen receptor [ER], the progesterone receptor [PR], and Her2) account for 10–20% of breast cancers, and have been reported to be more aggressive and associated with poorer survival than Her2 or hormone receptor-positive breast cancers2. Here, ERBB2 is linked to breast carcinoma.